[Skip to Content]
[Skip to Content Landing]

Prostate Cancer CME Series: Primary Care Clinical Case Scenarios

Learning Objectives
1. Recommend interventions and a treatment plan based on history, risk factors, and staging in the castration-sensitive prostate cancer (CSPC) setting
2. Develop assessment and monitoring skills in patients in the early stages of prostate cancer
0.25 Credit CME

Internet Enduring Material sponsored and presented by the Center for Continuing Medical Education at the Stanford School of Medicine.

Apply your knowledge and practice skills by examining five clinical case scenarios. This interactive learning module targets primary care clinicians who manage prostate cancer patients across the continuum of care. Each clinical case scenario allows you to work through history taking, investigations, differential diagnosis, and management. Using an interactive electronic health record (EHR) format, learners will explore early detection and intervention strategies for prostate cancer.

Sign in to take quiz and track your certificates

Stanford Medicine offers CME on a variety of topics that is evidence-based, references best practices supported by scientific literature and guidelines and is free of commercial bias. Learn more

Module not playing? Click here

Activity Information

All Rights Reserved. The content of this activity is protected by U.S. and International copyright laws. Reproduction and distribution of its content without written permission of its creator(s) is prohibited.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Financial Support Disclosure Statement: Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

Ali R Khaki, MD

Clinical Assistant Professor

Stanford Health Care (SHC)

Course Director, Faculty

Stocks or stock options, excluding diversified mutual funds-Merck and Company, Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Sanofi-Aventis (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Doximity (Relationship has ended).

Sumit Anil Shah, MD

Stanford

Course Director, Faculty

Advisor-Natera|Grant or research support-Genentech, Inc.

Ruth Adewuya, MD, CHCP

Managing Director, Center for Continuing Medical Education

Stanford University School of Medicine

Planner

Nothing to disclose

Marilyn Mejia, BA

Education Design Coordinator

Stanford University

Planner

Nothing to disclose

Commercial Support Disclosure Statement: This CME activity is supported by an educational grant from Astellas Pharma Global Development, Inc. and its collaborative partner, Pfizer, Inc.

References:
1.
American Cancer Society.  American Cancer Society Recommendations for Prostate Cancer Early Detection.  April 23 , 2021. Accessed July 19, 2022. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/acs-recommendations.html
2.
Urology Care Foundation.  Benign Prostatic Hyperplasia (BPH).  Sept 2021. Accessed July 19, 2022. https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph)
3.
Egerdie  B, Saad  F.  Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.  Can Urol Assoc J. 2010;4(2):129–135. doi:10.5489/cuaj.811Google Scholar
4.
Kotwal  AA, Mohile  SG, Dale  W.  Remaining Life Expectancy Measurement and PSA Screening of Older Men.  J Geriatr Oncol. 2012;3(3):196–204. doi:10.1016/j.jgo.2012.02.003Google Scholar
5.
Lerner  LB, McVary  KT, Barry  MJ,  et al.  Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management  [published correction appears in J Urol. 2021 Nov;206(5):1339].  J Urol. 2021;206(4):806–817. Google Scholar
6.
Barocas  DA, Boorjian  SA, Alvarez  RD,  et al.  Microhematuria: AUA/SUFU Guideline.  J Urol. 2020;204(4):778–786. doi:10.1097/JU.0000000000001297Google Scholar
7.
Park  HJ, Won  JE, Sorsaburu  S, Rivera  PD, Lee  SW.  Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.  World J Mens Health. 2013;31(3):193–207. doi:10.5534/wjmh.2013.31.3.193Google Scholar

Accreditation
In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
Stanford Medicine designates this Enduring Material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     
Close
Close
Close
Close

Name Your Search

Save Search
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close